Categories

Tag: IPO

#Healthin2Point00, Episode 183 | Oscar IPO, Plume, Sitka, & Alma

Today on Health in 2 Point 00, we’ve apparently got 58 different SPACs looking to acquire health tech companies – so looks like Jess and I will be staying busy! On Episode 183, Jess asks me about Oscar Health filing their S1 and all the dirt people are digging up for IPO, Plume raising $14 million for their full stack clinic for transgender people, Sitka raising $14 million, and Alma raising $28 million providing practice management software for mental health providers. —Matthew Holt

#Healthin2Point00, Episode 179 | Inauguration Day Edition

Today on Health in 2 Point 00, we’ve made it to Inauguration Day! On Episode 179, we have over $300 million in deals and a SPAC IPO. Jess asks for my take on Hims & Hers going public, primary care chatbot company K Health raising $132 million, digital pathology company Paige raising $100 million, and ACO management company Aledade getting another $100 million. —Matthew Holt

Accolade’s CEO Raj Singh: IPO Backstory & Pop Health Predictions for 2021

By JESSICA DaMASSA, WTF HEALTH

When Accolade went public in July at a $1.2B valuation, the BIG question facing the health tech unicorn pre-dated the covid-19 pandemic and the chaos facing its clientbase of large, self-insured employers: Could they scale? Raj Singh, Accolade’s CEO, tackles the question head-on, buoyed by customer growth that has doubled twice over a fiscal-year-and-a-half and an expanded need for his company’s high-touch, concierge health benefits navigation services. As beleaguered employers struggle with making sure their employees have the health benefits they need to weather the pandemic, Accolade’s focus on making sure that those benefits remain as cost-contained as possible seems to be more attractive than ever. What else is resonating with self-insured employers these days? Raj talks about what will (and won’t) change when it comes to population health management in 2021 and gives us a reality check on whether or not employers and their employees are really using digital health tools like Livongo, Virta, Hinge, Kaia, Ginger, et. al when baked into their benefits ecosystem.

#Healthin2Point00, Episode 157 | The phrase is “Takeout Speculation”!

Today on Health in 2 Point 00, Jess and I gossip about the wild rumor that UnitedHealthcare is acquiring Amwell. On Episode 157, we discuss Lark raising $55 million in a Series C along with a deal with Anthem to be their preferred DPP provider, Medicare Advantage plan Clover going public with a valuation of $3.7 billion, NOCD raising $12 million in a Series A providing specialized CBT and virtual OCD treatment, Cerebral raising $35 million in a Series A for its comprehensive digital mental health offerings, and Express Scripts adding to their digital health formulary with offerings targeting things like women’s health, tobacco cessation, muscle and joint pain, and more. —Matthew Holt

Health in 2 Point 00, Episode 150 | Sesquicentennial anniversary edition!

It’s Health in 2 Point 00’s 150th Episode or Sesquicentennial anniversary! On this episode, we have the return of Softbank money—$100M goes to Biofourmis platform for AI & Clinical Trials. Next, Amwell prices their IPO at $14-16 a share, and Grand Rounds raises $175 million led by the Carlyle Group. Finally, we have real foul play to report – former Zocdoc CEO Cyrus Massoumi filed a lawsuit accusing his fellow cofounders and CFO of foul play, so Jess asks me to dish the dirty details. —Matthew Holt

Health in 2 Point 00, Episode 132 | Accolade IPO, Somatus, NexHealth, Tatch & more

Today on Health in 2 Point 00, Jess and I cover some big news! Accolade has filed its IPO, so on Episode 132 I give my take on this health care navigation service. We also cover Somatus getting $64 million for chronic kidney disease care, NexHealth raising $15 million, Tatch raising $4.25 million for sleep apnea diagnosis, Simply Speak raising a $1.1 million seed round, and optimize.health raising $3.5 million for its remote monitoring platform. —Matthew Holt

What’s Ahead for Livongo & the Health Tech Market in 2020? | Glen Tullman, Livongo

By JESSICA DaMASSA, WTF HEALTH

What does Glen Tullman, Chairman of Livongo, expect from the health tech market in 2020? Livongo may have started a “race for the exits” in digital health with its 2019 IPO, and Glen says he “wants a healthy, consumer-facing digital health market” to help his own business thrive. Does that mean he anticipates more IPOs from the health tech sector this year? We get Glen’s predictions after we catch up on Livongo’s recent moves to partner with DexCom and test a new pathway to reimbursement via Express Scripts’ Digital Health Formulary.

Filmed at J.P. Morgan Healthcare Conference in San Francisco, January 2020.

Health Catalyst’s New Data-Driven Life Sciences Business | Sadiqa Mahmood, Health Catalyst

By JESSICA DaMASSA, WTF HEALTH

As if an IPO weren’t enough big news for Health Catalyst in 2019, the company also launched a brand-new life sciences business, basically setting forth a new solution for a completely new set of healthcare clients. Sadiqa Mahmood, Senior VP for Medical Affairs, explains how Health Catalyst is building off their deep expertise analyzing clinical care data and adding to it the molecular data typically collected by pharma companies, biotechs, med device manufacturers, and even digital health companies in order to open up a new era of precision medicine. The idea is to enable these innovators to better define patient cohorts for targeted therapies by creating a more robust data-set that integrates clinical measures. Was this strategy part of Health Catalysts’ larger plan to go public? How have life sciences companies responded so far? Sadiqa gives us some insight on Health Catalyst’s growth plans.

Filmed at Frontiers Health in Berlin, Germany, November 2019.

Health in 2 Point 00, Episode 108 | OneMedical IPO, Hinge Health, & Humana

Today on Health in 2 Point 00, we’re starting out with a riddle: what’s the similarity between the 49ers Super Bowl performance and digital health? Find out on Episode 108, where Jess and I discuss other news in health tech starting off with another IPO, OneMedical. Now worth more than Livongo at $2.7 billion, this went better than anyone could’ve expected. Hinge Health raises $90 million in a Series C round, offering physical therapy at home and tapping into the loads of waste that goes towards back surgeries. Finally, Humana partners with a private equity company to expand primary care centers, what is the deal with this? —Matthew Holt

A New Era for One Digital Health’s First Unicorns? | Maeve O’Meara, CEO, Castlight Health

BY JESSICA DAMASSA, WTF HEALTH

Is Castlight Health suffering a case of ‘first-mover’ curse? One of digital health’s first unicorns, Castlight Health, IPO’d back in 2014 with a valuation of over $3 billion dollars (reportedly, 107 times revenue) at a share price of $40. Today, the stock trades around $1.20, and the company has endured years of frustration from shareholders who’ve complained about customer churn and questioned the company’s business model. A recent change in leadership at the top of the organization has ushered in new CEO Maeve O’Meara, a long-time employee of the trailblazing company, who’s now responsible for blazing a new path toward forward herself. Refreshingly candid about the road ahead, Maeve explains how some new high-touch (but cost-effective) offerings are opening up new markets for the biz and hints at potential partnerships emerging with Big Tech. A must-watch for any digital health startup, investor, or industry analyst who wants longitudinal perspective on health tech’s market resilience and the importance of timing. Maeve, who was a health investor herself before joining Castlight, sums up the challenge of trailblazing tech in healthcare like this: “In healthcare, you always want to be one step ahead and not two steps ahead — you can get burned easily by being two steps ahead.”

Filmed at HLTH 2019 in Las Vegas, October 2019.

Continue reading…

Registration

Forgotten Password?